1. Home
  2. PYN vs IRD Comparison

PYN vs IRD Comparison

Compare PYN & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PYN
  • IRD
  • Stock Information
  • Founded
  • PYN 2002
  • IRD 2018
  • Country
  • PYN United States
  • IRD United States
  • Employees
  • PYN N/A
  • IRD N/A
  • Industry
  • PYN Investment Managers
  • IRD
  • Sector
  • PYN Finance
  • IRD
  • Exchange
  • PYN Nasdaq
  • IRD NYSE
  • Market Cap
  • PYN 33.5M
  • IRD 36.0M
  • IPO Year
  • PYN N/A
  • IRD N/A
  • Fundamental
  • Price
  • PYN $5.78
  • IRD $1.15
  • Analyst Decision
  • PYN
  • IRD Strong Buy
  • Analyst Count
  • PYN 0
  • IRD 1
  • Target Price
  • PYN N/A
  • IRD $8.00
  • AVG Volume (30 Days)
  • PYN 19.9K
  • IRD 145.1K
  • Earning Date
  • PYN 01-01-0001
  • IRD 02-24-2025
  • Dividend Yield
  • PYN 5.07%
  • IRD N/A
  • EPS Growth
  • PYN N/A
  • IRD N/A
  • EPS
  • PYN N/A
  • IRD N/A
  • Revenue
  • PYN N/A
  • IRD $8,381,000.00
  • Revenue This Year
  • PYN N/A
  • IRD N/A
  • Revenue Next Year
  • PYN N/A
  • IRD $29.37
  • P/E Ratio
  • PYN N/A
  • IRD N/A
  • Revenue Growth
  • PYN N/A
  • IRD N/A
  • 52 Week Low
  • PYN $4.84
  • IRD $0.81
  • 52 Week High
  • PYN $6.60
  • IRD $2.71
  • Technical
  • Relative Strength Index (RSI)
  • PYN 49.82
  • IRD N/A
  • Support Level
  • PYN $5.68
  • IRD N/A
  • Resistance Level
  • PYN $5.89
  • IRD N/A
  • Average True Range (ATR)
  • PYN 0.05
  • IRD 0.00
  • MACD
  • PYN 0.01
  • IRD 0.00
  • Stochastic Oscillator
  • PYN 47.19
  • IRD 0.00

About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest

PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: